Alx oncology highlights focused evorpacept development plan, clinical progress and corporate updates at r&d day webcast event

Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancers advancing novel egfr-targeted antibody-drug conjugate (adc) candidate, alx2004, into clinical-stage development with ind submission planned for q1 2025 company implements strategic prioritization, resource optimizations and reductions to extend cash runway into q4 2026 webcast featuring company leadership and external key opinion leaders to take place today at 6:00 a.m. pt/9:00 a.m.
ALXO Ratings Summary
ALXO Quant Ranking